Table 1

Correlations between FGF19 expression and clinicopathological parameters in 40 patients with HCC

Clinicopathological parameters

Patient number

Tumor FGF19 mRNA* (Mean ± SE)

P value


Age

< 65 years

23

0.007 ± 0.006

0.505

≥65 years

17

0.016 ± 0.014

Gender

Male

31

0.014 ± 0.009

0.319

Female

9

0.003 ± 0.002

Virus

HBV

4

0.058 ± 0.058

0.808

HCV

27

0.002 ± 0.001

None

9

0.017 ± 0.016

Miran Criteria

In

17

0.001 ± 0.000

0.194

Out

23

0.0019 ± 0.011

AFP

< 10 ng/mL

20

0.013 ± 0.012

0.194

≥ 10 ng/mL

20

0.009 ± 0.007

Tumor size

< 5 cm

20

0.001 ± 0.000

0.137

≥5 cm

20

0.021 ± 0.013

Histologic type of tumor

Well differentiated

6

0.001 ± 0.001

0.808

Moderately differentiated

31

0.014 ± 0.009

Poorly differentiated

3

0.002 ± 0.001

Formation of fibrous capsule

Present

39

0.011 ± 0.007

-------

Absent

1

0.0002

Capsular infiltration

Present

38

0.012 ± 0.007

0.718

Absent

2

0.0003 ± 0.0003

Septal formation

Present

30

0.014 ± 0.009

0.445

Absent

10

0.002 ± 0.002

Serosal invasion

Present

1

0.016

-------

Absent

39

0.011 ± 0.007

Portal invasion

Present

30

0.014 ± 0.009

0.449

Absent

10

0.002 ± 0.002

Hepatic vein invasion

Present

10

0.024 ± 0.023

0.269

Absent

30

0.007 ± 0.005

Intrahepatic metastasis

0.580

Present

22

0.008 ± 0.006

Absent

18

0.015 ± 0.013

Bile duct invasion

Present

1

0.232

-------

Absent

39

0.005 ± 0.004

Lymph node metastasis

Present

1

0.001

-------

Absent

39

0.011 ± 0.007

Pathological stage

II

7

0.0004 ± 0.0002

0.049

III

14

0.020 ± 0.016

IV

19

0.009 ± 0.007


HBV hepatitis B virus, HCV hepatitis C virus, AFP alpha-fetoprotein, S.E. standard error

Miura et al. BMC Cancer 2012 12:56   doi:10.1186/1471-2407-12-56

Open Data